ALLURION TECHNOLOGIES, INC. (ALUR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ALLURION TECHNOLOGIES, INC. (ALUR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001964979 false NONE NONE 0001964979 alur:CommonStockParValue00001PerShareMember 2026-07-17 2026-07-17 0001964979 alur:WarrantsToPurchase000378787SharesOfCommonStockEachAtAnExercisePriceOf303750PerShareOfCommonStockMember 2026-07-17 2026-07-17 0001964979 2026-07-17 2026-07-1
How this was made
The 30-second read
Why it matters
Immediate CEO departure without an interim or permanent replacement can affect investor confidence, analyst models, and near-term trading as the market reassesses leadership continuity and strategic execution.
Market read
This is a governance and leadership-change catalyst disclosed via 8-K, with explicit mention that no interim/permanent CEO has been appointed.
What to watch
The filing does not state the reason for resignation beyond no disagreement, so traders should watch for subsequent 8-Ks, board updates, or compensation/transition details that could reframe the narrative.
Background
The filing is an SEC Form 8-K (Item 5.02) reporting a CEO and board member resignation and related officer oversight arrangements.
Ticker impact
Allurion Technologies disclosed CEO Shantanu K. Gaur’s resignation effective immediately and that no interim or permanent CEO was appointed.
Likely near-term downside bias or elevated volatility until a replacement/transition plan is clarified.
The 8-K is a primary disclosure of an immediate CEO departure and explicitly states the board has not appointed an interim or permanent CEO, a material governance change for a public company.
Market effects
Could modestly raise perceived execution risk for small-cap medtech/health-tech peers if leadership churn is viewed as sector-relevant, though no direct peer linkage is provided.
Primarily US small-cap sentiment impact; no cross-regional operational details are disclosed.
No global macro or international operational changes are mentioned.
Counterpoint
The COO, Ojas Buch, will oversee day-to-day operations, which may limit operational disruption if the company already had a stable management bench.
Key entities
- issuerAllurion Technologies, Inc.
Company filing the 8-K; disclosed CEO resignation and day-to-day oversight by the COO.
- executiveShantanu K. Gaur, M.D.
Resigned as Chief Executive Officer and board member effective immediately; resignation not attributed to disagreement.
- executiveOjas Buch
Chief Operating Officer who will oversee day-to-day operations; compensation and title not modified.



